Tulisokibart + Placebo

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Radiographic Axial Spondyloarthritis

Conditions

Radiographic Axial Spondyloarthritis

Trial Timeline

Sep 26, 2025 → Feb 5, 2030

NCT ID

NCT07133633

About Tulisokibart + Placebo

Tulisokibart + Placebo is a phase 2 stage product being developed by Merck for Radiographic Axial Spondyloarthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07133633. Target conditions include Radiographic Axial Spondyloarthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07486960	Phase 2	Recruiting	Apr 22, 2026	Jan 11, 2030	Psoriatic Arthritis
NCT07133633	Phase 2	Recruiting	Sep 26, 2025	Feb 5, 2030	Radiographic Axial Spondyloarthritis
NCT06956235	Phase 2	Active	Jun 9, 2025	Jan 22, 2029	Hidradenitis Suppurativa
NCT06829225	Phase 1	Completed	Jun 13, 2024	Nov 11, 2024	Colitis, Ulcerative
NCT05270668	Phase 2	Active	Mar 29, 2022	Jul 31, 2029	Diffuse Cutaneous Systemic Sclerosis

Competing Products

6 competing products in Radiographic Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	52
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	77
Secukinumab + Placebo	Novartis	Phase 3	77
Secukinumab + Placebo + Secukinumab	Novartis	Approved	85
Secukinumab + Placebo	Novartis	Phase 3	77
Bimekizumab	UCB	Phase 3	74

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved